Selected Publications
Reckless, J and Grainger, DJ. (1999) Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines.
Biochem. J. 340:803-811.
Reckless J, Tatalick LM, Grainger DJ. (2001)
The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-alpha accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo.
Immunology 103:244-54
Beech JS, Reckless J, Mosedale DE, Grainger DJ, Williams SC, Menon DK. (2001)
Neuroprotection in ischemia-reperfusion injury: an antiinflammatory approach using a novel broad-spectrum chemokine inhibitor.
J Cereb Blood Flow Metab. 21:683-9.
Fox DJ, Reckless J, Warren SG, Grainger DJ. (2002)
Design, synthesis and preliminary pharmacological evaluation of N-alkyl 3-aminoglutarimides as broad spectrum chemokine inhibitors in vitro and anti-inflammatory agents in vivo.
J. Med. Chem. 45:360-70
Naidu BV, Farivar AS, Krishnadasan B, Woolley SM, Grainger DJ, Verrier ED, Mulligan MS. (2003)
Broad-spectrum chemokine inhibition ameliorates experimental obliterative bronchiolitis.
Ann Thorac Surg. 75:1118-22.
Grainger DJ, Reckless J, McKilligin E. (2004)
Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice.
J Immunology 173:6366-75
Fox D, Reckless J, Wilbert S, Greig I, Warren SG, Grainger DJ. (2005)
Identification of 3-(acylamino)azepan-2-ones as stable broad-spectrum chemokine inhibitors (BSCI) resistant to metabolism, in vivo.
J. Med. Chem. 48:867-874.
Grainger DJ, Lever AM. (2005)
Blockade of chemokine-induced signalling inhibits CCR5-dependent HIV infection in vitro without blocking gp120/CCR5 interaction.
Retrovirology 2:23
Grainger DJ, Reckless J, Fox DJ. (2005)
Broad spectrum chemokine inhibitors related to NR58-3.14.3.
Mini Rev Med Chem. 5:825-32
Miklos S, Mueller G, Chang Y, Bouazzaoui A, Spacenko E, Schubert TE, Grainger DJ, Holler E, Andreesen R, Hildebrandt GC.(2009)
Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease.
Int J Hematol. 89:383-97.
Reckless J, Piercy V, Langley K, Purvis I, Fox D & Grainger DJ (2009)
FX125L, a novel small molecule chemokine inhibitor, attenuates neutrophil accumulation in a model of allergic asthma and exhibits a superior efficacy profile to dexamethasone or monteleukast.
Late Breaking oral presentation (abstract 1418) at the XXVIII Congress of the European Academy of Allergy and Clinical Immunology, EAACI 2009, held in Warsaw, Poland on 6-10 June 2009.
Wiesel, P.; Cooper, R.; Wang-Smith, L.; Reckless, J.;Champion, K. J.; Petrolese, V.;& Grainger, D. (2009)
First clinical experience with FX125L, an anti-inflammatory oral small molecule with an entirely novel mechanism of action.
Oral presentation (abstract #682412) at ACAAI’s 2009 Annual Meeting, held in Miami Beach, Florida (USA) on 5-10 November 2009.